Figure 7. RT+TLR9 agonist treatment prevents tumor metastasis and improves survival.
The number of lung metastase in wild type C57BL/6 mice treated with either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist was counted and compared (A). The survival rate of mice from each group after treatment was analyzed using Log-rank (Mantel-Cox) Test (B).